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Stearoyl-CoA desaturase-1 (SCD1), a critical
regulator of energy metabolism, catalyzes the
synthesis of monounsaturated fats. To under-
stand the tissue-specific role of SCD1 in energy
homeostasis, we used Cre-lox technology to
generate mice with a liver-specific knockout of
Scd1 (LKO). LKO mice were protected from
high-carbohydrate, but not high-fat (HF), diet-
induced adiposity and hepatic steatosis. Addi-
tionally, on a high-sucrose, very low-fat (HSVLF)
diet, lipogenesis and levels of nuclear SREBP-1
and ChREBP were significantly decreased in
the livers of LKO relative to Scd1lox/lox (Lox)
mice. HSVLF feeding in LKOmice caused hypo-
glycemia and hepatic carbohydrate reduction
due to an impairment of gluconeogenesis.
Oleate, but not stearate, supplementation nor-
malized adiposity, gluconeogenesis, triglycer-
ide secretion, and hepatic lipogenesis of LKO
mice. These results indicate that hepatic
SCD1 expression (and thus, oleate) is required
for carbohydrate-induced adiposity, but SCD1
inhibition in extrahepatic tissues is required to
protect mice from HF-induced obesity and
insulin resistance.
INTRODUCTION
Obesity develops as a complex result of genetic, meta-
bolic, and environmental factors. The diverse clinical char-
acteristics of obesity illustrate the complexity of this
disease, involving the dysregulation of several metabolic
pathways and multiple genetic targets. The increasing
prevalence of obesity and the metabolic syndrome
heightens the requirement for new approaches for both
the management and prevention of these diseases. In or-
der to understand the etiology, it is critical to appreciate484 Cell Metabolism 6, 484–496, December 2007 ª2007 Elseviethe nature of the multiple gene-nutrient interactions rele-
vant to obesity and metabolic syndrome. Overnutrition,
including excess consumption of fats and carbohydrates,
clearly plays a crucial role in the development and pro-
gression of this condition. Genetic factors interact with
dietary nutrients, such as fatty acids and carbohydrates,
thereby affecting the predisposition to the metabolic syn-
drome as well as the metabolic responsiveness to altered
dietary fat and carbohydrate intake (Slyper, 2004). Under-
standing the biological impact of gene-nutrient interac-
tions provides a key insight into the pathogenesis and
progression of obesity.
The mammalian stearoyl-CoA desaturase-1 (SCD1) is
proposed to be required for the development of diet-
induced obesity and its associated disorders. SCD1 is
amember of the fatty acid desaturase family and catalyzes
mainly the conversion of stearoyl-CoA to oleoyl-CoA,
which is a major substrate for triglyceride (TG) synthesis.
We previously have demonstrated that mice with a global
deletion of Scd1 (GKO) are resistant to high-fat (HF) diet-
and genetically induced obesity (Cohen et al., 2002;
Ntambi et al., 2002). The global SCD1 deficiency also
prevented the liver steatosis observed in a number of
mouse models, including mice fed high-carbohydrate
(HC) and HF diets, ob/ob, PPARa/, and aP2-SREBP1c
lipodystrophic mice (Asilmaz et al., 2004; Cohen et al.,
2002; Miyazaki et al., 2004a, 2004b; Ntambi et al., 2002).
The reduced adiposity of GKO mice is also associated
with increased insulin sensitivity (Flowers et al., 2007;
Ntambi et al., 2002). Recent studies using in vivo antisense
oligonucleotide (ASO) inhibition of Scd1 also showed the
prevention of diet-induced obesity and hepatic insulin
resistance (Gutierrez-Juarez et al., 2006; Jiang et al.,
2005). Although these studies clearly illustrated that
SCD1 expression is involved in the development of obesity
and insulin resistance, questions remain in the elucidation
of the role of SCD1: (1) where is SCD1 deficiency most im-
portant for eliciting these metabolic effects, and (2) how
does SCD1 or its product oleate modulate metabolism?
In this study, we investigated the physiological role of
SCD1 in liver by creating liver-specific Scd1 knockout
(LKO) mice. We found that LKO mice were protectedr Inc.
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tosis. Consistent with the prevention of carbohydrate-in-
duced adiposity, LKO mice displayed a marked decrease
in the rate of lipogenesis with decreased expression of
sterol regulatory element-binding protein (SREBP)-1c
and carbohydrate response element binding protein
(ChREBP) and their target genes. Liver-specific SCD1
deficiency caused a severe impairment of gluconeogene-
sis, resulting in hypoglycemia and depletion of hepatic
carbohydrate metabolites such as glucose-6-phosphate
(G6P) and xylulose-5-phosphate (X5P). These results
demonstrate a vital role of hepatic SCD1 in carbohy-
drate-induced adiposity and lipogenesis.
RESULTS
Global SCD1 Deficiency Protects Mice
from Adiposity
We have previously shown that GKOmice on a SV129 ge-
netic background are protected from obesity elicited by
a milk fat-based HF diet (Ntambi et al., 2002). To verify
that global SCD1 deficiency also prevents obesity in
mice on a C57BL/6 background, we fed C57BL/6 GKO
mice a chow diet, a HC diet (10% kcal from fat) enriched
in starch and sucrose, or a lard-based HF diet (60% kcal
from fat). GKO mice were protected from both HC and
HF diet-induced adiposity (see Table S1 and Figures
S1A and S1B in the Supplemental Data available with
this article online). White adipose tissue (WAT) weights
of GKO mice on the HF and HC diets were 80% and
75% lower, respectively, than that of their wild-type coun-
terparts (Figure S1B). GKOmice were also protected from
both HF and HC diet-induced fatty liver (Table S1). GKO
mice showed enhanced glucose tolerance, lower fasting
plasma glucose, and improved insulin sensitivity under
all three dietary conditions (Table S1 and Figures S1C–
S1E). Plasma TG levels were decreased in GKO mice on
both HF and HC diets, but not chow diet (Table S1).
Food intake was higher in GKO mice under all dietary
conditions tested (Table S1). Monounsaturated fatty acid
(MUFA; 16:1n-7, 18:1n-9 and 18:1n-7), palmitate (16:0)
and linoleate (18:2n-6) content were significantly
decreased in hepatic TG of GKO under all three dietary
conditions (Table S2).
Generation of Mice with a Floxed Allele of Scd1
We generated mice with a floxed allele of Scd1 to allow its
deletion in different cell types and tissues. Scd1lox/+ mice
were crossed six times with C57BL/6 mice. Scd1lox/+
mice, when bred to homozygosity (Scd1lox/lox, Lox),
were phenotypically indistinguishable from wild-type
mice and showed normal SCD1 protein expression and
activity (Figure 1), indicating the loxP sites and NEO
cassette did not interfere with SCD1 expression. To gen-
erate liver-specific Scd1 knockout mice, we crossed
Scd1lox/lox mice to an albumin promoter Cre recombi-
nase-expressing strain on a C57BL/6 background to
obtain Scd1lox/+;Cre+ mice. Subsequently, we crossed
these mice to Lox mice to yield Scd1lox/lox;Cre+ (LKO)Cell Memice. Unlike GKO mice showing alopecia and closed
eyes (Miyazaki et al., 2001b), LKO mice were indistin-
guishable from both wild-type and Lox mice. To confirm
deletion ofScd1 in the LKOmice, we analyzed recombina-
tion of the Scd1flox allele by PCR in liver DNA. In 8-week-
old LKO mice, the recombination allele was detected in
liver (Figure 1B), but not other tissues (data not shown).
SCD1 Western blot and SCD activity assay confirmed
the lack of SCD1 expression in liver, but not other tissues
from overnight-fasted LKO mice refed a fat-free HC diet
(Figures 1C and 1D). Scd2 mRNA in liver, palmitoyl-CoA
desaturase (Scd3) mRNA in Harderian gland, and Scd4
mRNA in heart were similar between wild-type mice,
Lox, and LKO mice (data not shown). Consistent with
lack of SCD1 activity, Figure 1E shows that liver of
fasted/refed LKOmice had lower levels of SCD1 products
including palmitoleate (16:1) and oleate (18:1).
LKO Mice Are Protected from HC, but Not HF,
Diet-Induced Adiposity
To test whether liver-specific Scd1 deletion produces the
same metabolic phenotypes as seen in GKO mice, male
LKO and Lox mice were placed on a chow, HF or HC
diet at 8 weeks of age. On a chow diet, there were no dif-
ferences in body weight, adiposity, food intake, or other
biochemical parameters between LKO and Lox mice
(Figure 2A and Table S3). Unexpectedly, LKO mice and
Lox littermate controls on a HF diet showed comparable
gain of body weight during the 18 week feeding period
(Figure 2A). Fat pad weights were also similar between
HF-fed Lox and LKO mice (Figure 2C). In contrast to
in vivo ASO-mediated inhibition of Scd1 (Gutierrez-Juarez
et al., 2006), liver-specific Scd1 deletion also did not
improve glucose clearance and insulin sensitivity under
theHF condition (Figures 2D–2F and Table S3). Othermet-
abolic parameters in Lox and LKO mice fed the HF diet
were also not different (Table S3). It is important to note
that a recent study by Jiang et al. in which Scd1 was in-
hibited by in vivo ASO treatment also used the same
C57BL/6 genetic background and lard-based HF diet
(Jiang et al., 2005).
We next fed Lox and LKO mice a HC diet for 18 weeks,
which revealed several phenotypic differences. Similar to
GKO mice, LKO mice on HC diet had markedly reduced
weight compared to lox counterparts (Figure 2B and
Figure S1A). Fat pad weights, including gonadal, retroper-
itoneal, and inguinal, were reduced by49%–59% in LKO
mice as compared to Lox controls (Figure 2C). No signifi-
cant difference was observed for plasma glucose and
insulin levels, glucose clearance, and insulin sensitivity
(Figure 2D–2F and Table S3). Liver histological examina-
tion indicated that LKO mice were protected from HC,
but not HF, diet-induced liver steatosis (Figure 3A). Liver
TG content was decreased by 69% in LKO mice fed
a HC diet compared to Lox controls (Figure 3B). Plasma
TGwas significantly lower in LKOmice relative to Lox con-
trols when fed the HC diet, but similar in chow- and HF-fed
mice (Figure 3C). Lipoprotein profiles showed a significant
reduction of TG in the VLDL fraction of LKO mice fed thetabolism 6, 484–496, December 2007 ª2007 Elsevier Inc. 485
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Scd1 Knockout Mice
(A) Scheme of targeting construct design and
simplified restriction map of the Scd1 locus.
(B) PCR analysis: DNA from LKO livers
(Scd1lox/lox;Cre/+) generated a 180 bp fragment
showing appropriate recombination in the
Scd1 gene. DNA from Lox control liver pro-
duced a larger fragment.
(C) Western blot analysis of SCD1 protein: mi-
crosomes were isolated from livers of over-
night-fasted LKO and Lox male mice refed
a high carbohydrate fat-free diet for 24 hr.
(D) SCD1 activity: SCD1 activity in liver, adi-
pose, kidney, and skeletal muscle (SM) were
measured in the presence of 50 mgmicrosomal
protein, NADH, and 14C-stearoyl-CoA.
(E) Fatty acid composition in liver of LKO and
Lox mice under fasting/refeeding conditions:
male mice were fasted overnight and were
then refed a high carbohydrate fat-free diet
for 24 hr. Palmitoleate (16:1) and oleate (18:1)
were significantly reduced in liver of LKO
mice. Results are expressed as mean ± SEM.HC diet (Figure 3D), but only a modest decrease in chow-
and HF-fed mice (data not shown). Hepatic glycogen con-
tent was lower in LKO mice fed the HC diet (Figure 3E).
Plasma cholesterol levels (Table S3) and cholesterol
FPLC profiles (data not shown) were not affected by liver
SCD1 deficiency.
To understand how liver-specific SCD1 deficiency de-
creased carbohydrate-induced adiposity and liver steato-
sis, we analyzed genes involved in TG metabolism includ-
ing lipogenesis and fatty acid oxidation. There was no
significant difference of gene expression pattern between
LKO and Lox mice on the chow and HF diets (Figure 3G
and data not shown). However, the effect of the HC diet
on hepatic lipogenic gene expression in LKO mice was
striking. The expression of mRNAs encoding enzymes for
lipogenesis including fatty acid synthase (FAS), acetyl-
CoA carboxylase (ACC), and Elovl6 were decreased by
69%, 49%, and 66%, respectively, in liver of LKO mice
fed a HC diet (Figure 3G). We previously reported that
GKO mice on 129 SvEv background exhibited higher
mRNAs encoding enzymes in fatty oxidation (L-CPT1,
AOX and VLCAD) compared to wild-type mice (Miyazaki
et al., 2004b; Ntambi et al., 2002). However, mRNAs for
fatty acid oxidation genes were not altered in the liver of
LKOmice under these dietary conditions (data not shown).486 Cell Metabolism 6, 484–496, December 2007 ª2007 ElsevTo confirm that the decreased mRNAs for the lipogenic
enzymes led to a reduction of lipid synthesis in the liver of
LKO mice, we measured in vivo hepatic lipogenesis using
3H-water as a tracer. LKO mice fed the HC diet exhibited
an 85% decrease in the rate of fatty acid synthesis com-
pared to Lox controls (Figure 3F), while rate of cholesterol
synthesis was not affected (data not shown). Thus,
hepatic SCD1 deficiency is sufficient to impair the normal
upregulation of hepatic fatty acid synthesis in response to
a HC diet.
To validate that liver-specific SCD1 deficiency depletes
MUFA content under HF and HC diet feeding similar to
global SCD1 deficiency, we analyzed the fatty acid com-
position of liver TG in Lox and LKO mice. HC diet feeding
in LKO mice lowered MUFA contents of 16:1n-7, 18:1n-9,
and 18:1n-7 by 73%, 82%, and 74%, respectively, similar
to GKO mice (Tables S2 and S4). However, liver TG fatty
acid composition of LKO mice was similar to that of Lox
mice after HF diet feeding (Table S4).
Hepatic Carbohydrate Metabolites Are Decreased
in LKO Mice
To better understand the mechanisms involved in the re-
duced HC-induced lipogenesis and to enhance the effect
of carbohydrate on lipogenesis, we fed a high-sucroseier Inc.
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High-Carbohydrate but Not High-Fat
Diet-Induced Adiposity
(A) Body weight of 8-week-old male Lox and
LKO mice (n = 10) fed either chow or HF diet
for 18 weeks.
(B) Body weight of an 8-week-old male (n = 10)
fed a HC diet for 18 weeks. Statistical analysis
was performed by repeated one-way ANOVA.
(C) The weight of major white adipose tissue
(WAT) of Lox and LKO male mice fed chow,
HF, or HC diet after 18 weeks of feedings. An-
imals were fasted for 4 hr and sacrificedwith an
isoflurane overdose. *p < 0.05 and **p < 0.001
versus Lox counterparts (One-way ANOVA
using Student-Newman post-hoc test).
(D) Glucose tolerance test: after 15 week of
feedings, 2 g/kg body weight of glucose was
administrated with oral gavage and blood
was drawn at 0, 20, 40, and 90 min after the in-
jection.
(E) Plasma insulin level during GTT: plasma in-
sulin level was analyzed with a RIA kit.
(F) Insulin tolerance test: after 15 weeks of
feedings, 0.75 U/kg body weight of human in-
sulin was intraperitoneally administrated and
blood was drawn at 0, 15, 30, 45, and 60 min
after the injection. Results are expressed as
mean ± SEM.very low-fat diet (HSVLF) to LKO mice for 2 weeks. Con-
sistent with long-term feeding of theHCdiet shown above,
LKO mice were protected from carbohydrate-induced
adiposity in the short-term (Table 1; Table S5). Despite
no difference in food intake on HSVLF diet, the body and
WAT weights of LKO mice were 10% and 51% lower,
respectively, than those of Lox controls (Figure 4A; Table
1; Table S5). Hepatic and plasma TG was also reduced by
49% and 20%, respectively, in HSVLF-fed LKOmice rela-
tive to HSVLF-fed Lox mice (Figure 4B; Table 1; Table S5).
Hepatic levels of ceramides, diacylglycerols (DAG), free
fatty acids, phospholipids, and cholesteryl esters were
not significantly different between Lox and LKO mice fed
either the chow or HSVLF diet (Table 1; Figure S2). We
previously reported that GKO mice fed the HSVLF diet
for 10 days developed hypoglycemia, hypercholesterol-
emia, loss of body weight, and many cholestasis-like
phenotypes (Flowers et al., 2006). Similar to GKO mice,
plasma glucose and hepatic glycogen levels were re-
duced in HSVLF LKO mice (Figures 4C and 4D; Table 1)
despite the fact that there is no difference in the activitiesCell Metof glycogen synthase or phosphorylase (data not shown).
In addition, many carbohydrate metabolites such as G6P,
fructose-6-phosphate (F6P), fructose 2,6-bisphosphate
(F2,6BP), and X5P were significantly reduced in liver of
LKO mice fed the HSVLF diet (Figures 4E and 4F; Table
1). LKO mice fed the HSVLF diet also developed hyper-
cholesterolemia (Table 1). However, this increase is due
to increased LDL and HDL cholesterol (Figure S3) unlike
the lipoprotein-X and cholestasis-related plasma choles-
terol changes observed in HSVLF-fed GKO mice (Flowers
et al., 2006). Additionally, plasma bile acids were not
elevated by HSVLF feeding in LKO mice (data not shown)
unlike the previously reported observation in GKO mice
(Flowers et al., 2006).
Liver-specific SCD1 deficiency completely blocked car-
bohydrate-induced lipogenesis (Figure 5A) and reduced
hepatic mRNAs encoding lipogenic enzymes including
FAS, ACC, Elvol6, malic enzyme, LPK, and glucose-
6-phosphate dehydrogenase (Figure 5; Table S6). Liver-
specific SCD1 deficiency decreased mRNA levels of both
Srebf1 (SREBP-1c) and Mlxipl (ChREBP), which are twoabolism 6, 484–496, December 2007 ª2007 Elsevier Inc. 487
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High-Carbohydrate but Not High-Fat,
Diet-Induced Liver Steatosis
(A) Liver histology: the tissue was fixed with
10% buffered-formalin and was stained with
hematoxylin and eosin.
(B and C) Hepatic (B) and Plasma (C) TG: lipids
were extracted from liver of animals indicated
in Table S3. Hepatic TG contents were ana-
lyzed with GLC. Plasma TG was analyzed
with a colorimetric assay kit. Each bar repre-
sents the mean ± SEM of n = 5–10 mice per
group. *p < 0.01 (one-way ANOVA using Stu-
dent-Newman post-hoc test).
(D) FPLC analysis: lipoproteins in animals fed
a HC diet were fractionated on a Superose 6
10/300 GL FPLC column. Each fraction was
used for cholesterol and TG determinations.
Cholesterol level was similar between Lox
and LKO mice.
(E) Hepatic glycogen: livers of animals indi-
cated in Table S3were used. Glycogen content
was measured by a colorimetric assay.
(F) Hepatic fatty acid synthesis: male animals
fed a HC diet for 18 weeks were fasted for
2 hr and 50 mCi of 3H2O was intraperitoneally
injected. Incorporation of 3H-radioactivity into
sterols and fatty acids was expressed as
mmol per hour per gram of liver. Each bar rep-
resents the mean ± SEM of n = 5 male mice
per group. *p < 0.01 compared to Lox mice
fed a HC diet (Student’s t test).
(G) Lipogenic gene expressions: RT-qPCRwas
performed on an ABI 7500 Fast instrument us-
ing gene-specific primers. Each bar indicated
the mean ± of n = 4–6 mice per group. Data
are presented relative to mRNA of acid ribo-
somal binding protein (Arbp) in the same sam-
ples. *p < 0.05 compared to Lox counterparts
(one-way ANOVA using Student-Newman
post-hoc test).major transcription factors involved in transcriptional reg-
ulation of lipogenesis by carbohydrates (Figure 5B). Addi-
tionally, the nuclear contents of SREBP-1c and ChREBP
were decreased in HSVLF-fed LKO mice (Figure 5C).
There was no difference in Srebf2 (SREBP-2) mRNA
and protein (Table S6; Figure 5C). The expression level
of genes encoding enzymes involved in fatty acid oxida-
tion (LCPT1, MCAD, VLCAD, and AOX), cholesterol
metabolism (LDL receptor, HMG-CoA synthase, ABCG5,
and ABCG8), and mitochondrial metabolism (Tfam, cyto-
chrome c synthase, cytochrome c oxidase II, and cyto-
chrome c oxidase IV) was not different between Lox and
LKO mice fed the chow or HSVLF diet (Table S6).
Hepatic Oleate Is Required for Lipogenic Induction
in LKO Mice
To examine whether reduction of oleate (18:1n-9), a major
SCD1 product, or accumulation of stearate (18:0) contrib-
utes to the antilipogenic and hypoglycemic effect of SCD1
deficiency, we supplemented 20%weight of either triolein
or tristearin to theHSVLFdiet and fed them to Lox and LKO488 Cell Metabolism 6, 484–496, December 2007 ª2007 Elsevmice for 10 days. Triolein, but not tristearin, supplementa-
tion increased adiposity and hepatic TG in LKO mice (Fig-
ures 4A and 4B). Interestingly, the hepatic ceramide level
was significantly higher in LKO mice fed HSVLF diet sup-
plemented with tristearin (Figure S2). In addition, oleate,
but not stearate, feeding prevented the decreased plasma
glucose and hepatic levels of glycogen, G6P, and X5P in
LKO mice (Figures 4C–4F). Srebf1 (SREBP-1) and Mlxipl
(ChREBP) mRNAs and proteins were also normalized
when oleate, but not stearate, was supplemented (Figures
5B and 5C). The expression of mRNAs encoding enzymes
of lipogenesis and glycolysis, including FAS, ACC, Elovl6,
and liver pyruvate kinase (LPK), were increased as the re-
sult of SREBP-1 and ChREBP inductions (Figures 5D and
5E). We next tested whether hepatic SCD1 deficiency al-
ters TG secretion from liver. The HSVLF diet increased
the rate of TG secretion in Lox mice but failed to increase
it in LKOmice. Oleate but not stearate feeding normalized
the impaired hepatic TG secretion in LKOmice (Figure 5F).
Since treatment of FAS liver-specific knockout (FASLKO)
micewith aPPARa agonist rescued the high-carbohydrate,ier Inc.
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Genotype Diet Units Lox Chow LKO Chow Lox HSVLF LKO HSVLF
Body weight g 19.88 ± 0.75 19.60 ± 0.15 19.64 ± 0.55 17.62 ± 0.70*
Food intake g 4.04 ± 0.08 3.97 ± 0.14 3.28 ± 0.04 2.84 ± 0.05
Liver weight g 0.99 ± 0.15 0.82 ± 0.11 0.97± 0.08 0.93 ± 0.10
WAT weight g 0.19 ± 0.04 0.17 ± 0.05 0.31 ± 0.11 0.15 ± 0.09*
Plasma
Lactate mg/dl 48.80 ± 12.63 44.51 ± 3.57 48.65 ± 8.11 41.05 ± 3.93
TG mg/dl 59.61 ± 3.64 44.51 ± 4.26 70.86 ± 11.02 56.90 ± 3.58*
Cholesterol mg/dl 91.45 ± 7.33 92.55 ± 5.00 105.7 ± 3.07 157.7 ± 18.60*
Insulin ng/ml 0.27 ± 0.07 0.27 ± 0.02 0.31 ± 0.01 0.29 ± 0.02
Liver
Glucose mmol/g 7.02 ± 1.38 7.97 ± 0.68 12.81 ± 0.89 2.10 ± 1.54*
G6P mmol/g 0.36 ± 0.02 0.38 ± 0.00 0.42 ± 0.05 0.08 ± 0.02*
F6P mmol/g 0.06 ± 0.01 0.05 ± 0.00 0.04 ± 0.00 0.02 ± 0.01*
F1,6P2 mmol/g 0.05 ± 0.00 0.06 ± 0.01 0.05 ± 0.01 0.05 ± 0.01
F2,6P2 mmol/g 4.55 ± 0.11 5.16 ± 0.25 5.27 ± 0.40 3.47 ± 0.27*
DAP mmol/g 0.08 ± 0.01 0.07 ± 0.00 0.06 ± 0.01 0.06 ± 0.00
GAP mmol/g 0.04 ± 0.00 0.04 ± 0.01 0.03 ± 0.00 0.03 ± 0.00
Pyruvate mmol/g 0.26 ± 0.03 0.27 ± 0.09 0.25 ± 0.03 0.23 ± 0.01
Lactate mmol/g 0.74 ± 0.09 0.92 ± 0.22 0.73 ± 0.18 0.58 ± 0.13
X5P mmol/g 0.04 ± 0.00 0.04 ± 0.00 0.14 ± 0.02 0.05 ± 0.03*
Glycogen mg/g 20.48 ± 4.46 23.25 ± 2.21 37.36 ± 2.87 6.13 ± 1.27*
ATP mmol/g 1.58 ± 0.13 1.63 ± 0.08 2.19 ± 0.35 1.27 ± 0.07*
TG mmol/g 16.40 ± 0.40 14.36 ± 0.76 39.74 ± 4.12 20.38 ± 0.40*
CE mmol/g 3.85 ± 0.18 3.06 ± 0.15 5.82 ± 0.74 5.52 ± 0.49
PL mmol/g 25.21 ± 0.55 24.65 ± 0.80 44.39 ± 4.29 49.38 ± 2.42
Females (n = 4–7) were fedwith either chowor HSVLF diet for 14 days and sacrificed by carbon dioxide asphyxiation after a 4 hr fast.
Values are mean ± SE. G6P, glucose-6-phosphate; F6P, fructose-6-phosphate; F1,6P2, fructose 1,6-bisphosphate; F2,6BP, fruc-
tose 2,6-bisphosphate; DAP, dihydroxyacetone phosphate; GAP, glyceraldehyde-3-phosphate; X5P, xylulose-5-phosphate; TG,
triglyceride; CE, cholesteryl ester; PL, phospholipid.
* <0.05 compared to Lox counterparts.fat-free diet-induced hypoglycemia (Chakravarthy et al.,
2005), we wondered whether a PPARa agonist treatment
would rescue the metabolic phenotypes observed in
HSVLF-fed LKO, such as hypoglycemia and reduced
adiposity. We supplemented the HSVLF diet with 0.1%
weight of the potent PPARa agonist WY14,643 and fed
it to wild-type, Lox, and LKO mice for 10 days. The
WY14,643-supplemented HSVLF diet failed to increase
adiposity and restore euglycemia in LKO mice (Figures
S4A and S4B). However, the WY14,643-supplemented
HSVLF diet also reduced adiposity and plasma glucose
in wild-type and Lox mice (Figures S4A and S4B).
WY14,643 induced PPARa target genes including
Cyp4a10, Cpt1a (L-CPT1), Acox1 (AOX), Acadm (MCAD),
Lpl, and Ucp2 in both Lox and LKO mice (Figure S4C),
indicating an appropriate response to PPARa activation.Cell MImpaired Gluconeogenesis in LKO Mice
Is Rescued by Oleate
To examine whether liver-specific SCD1 deficiency in
conjunction with a high-carbohydrate feeding impairs glu-
coneogenesis, we performed a pyruvate tolerance test on
the HSVLF fed-mice. HSVLF diet feeding in LKO mice
impaired glucose production from pyruvate (Figure 6A).
In addition, oleate supplementation to HSVLF diet rescued
the impairment of gluconeogenesis in LKO mice. To fur-
ther define the mechanisms underlying the HSVLF-
induced hypoglycemia, we analyzed the mRNA abun-
dance of genes and the phosphorylation state of proteins
(p-IRS-1, p-Akt, p-ERK, and p-AMPK) involved in glucose
metabolism and insulin signaling. There were no differ-
ences in p-IRS-1, p-Akt, p-ERK, and p-AMPK levels in
HSVLF-fed mice (Figure 6B). Additionally, the expressionetabolism 6, 484–496, December 2007 ª2007 Elsevier Inc. 489
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tase) and Pck1 (PEPCK) were not different in HSVLF-fed
mice (Figure 6). Interestingly, stearate induced Ppargc1a
(PGC-1a) and Pck1 (PEPCK) gene expression in LKO
mice despite their hypoglycemia (Figure 6). Inhibition of
fatty acid oxidation is known to diminish gluconeogenesis,
which results in hypoglycemia (Kersten et al., 1999; Spie-
kerkoetter et al., 2006; Xuet al., 2002). Despite a significant
reduction of hepatic ATP in LKO fed HSVLF diet (Table 1),
there were no differences in plasma b-hydroxybutyrate
(BHA) (Table S5) or expression of fatty acid oxidation
genes (Table S6). On the other hand, HSVLF feeding in
LKO mice increased genes involved in thermogenesis,
such as Ppargc1a (PGC-1a), Adrb2 (b2 adrenergic recep-
tor), and uncoupling proteins (Ucp-1, Ucp-2, Ucp-3, and
Slc25a14 (UCP-5), which were reversed by oleate but
not stearate supplementation (Table S6; Figure 6). Al-
though we observed no difference between HSVLF-
fed Lox and LKO mice in core body temperature or in
response to a 24 hr cold tolerance test (data not shown),
Figure 4. Altered Carbohydrate Metabolism in LKO Mice Is
Revealed by High-Sucrose, Very Low-Fat Feeding
(A) Gonadal fat weight, (B) Hepatic TG, (C) Plasma Glucose, (D)
Hepatic glycogen, (E) Glucose-6-phosphate (G6P), and (F) Xylulose-
5-phosphate (X5P) content in Lox and LKO mice. Eight-week-old ani-
mals (n = 6, 4 males and 2 females) were fed with chow, HSVLF, and
HSVLF supplemented with 20% either tristearin (18:0) or triolein
(18:1n-9) for 10 days. For carbohydrate measurements, liver samples
were homogenized with 0.5 M perchloric acid. *p < 0.05 and **p <
0.001 compared to Lox counterparts (one-way ANOVA using Stu-
dent-Newman post-hoc test). Results are expressed as mean ± SEM.490 Cell Metabolism 6, 484–496, December 2007 ª2007 Elseviethe gene expression results suggest that a localized
enhancement of hepatic uncoupling in HSVLF diet-fed
LKO mice leads to ATP reduction, causing hypoglycemia
through inhibition of gluconeogenesis.
DISCUSSION
The goal of this study was to determine the role of liver-de-
rived MUFA synthesis to the antiobesity phenotypes
observed in both GKO mice and mice treated with
Scd1-targeted ASO (Ntambi et al., 2002; Jiang et al.,
2005). In both GKO mice and ASO-treated mice, SCD1
deficiency causes decreased lipogenesis and increased
fatty acid oxidation. These antiobesity effects occur de-
spite the high abundance of MUFA in the lard-enriched
HF diet (40%–50% MUFA). This suggests that endoge-
nous MUFA synthesis yields a source of MUFA distinct
from the dietary MUFA pool, which acts as a metabolic
switch influencing the balance of energy storage versus
energy oxidation. However, to completely understand
the role of MUFA synthesis in metabolism, it is necessary
to understand the tissue-specific MUFA contribution to
the phenotype of the whole organism. We generated
conditionally null Scd1lox/lox mice harboring loxP recombi-
nation sites flanking exon 3, which contains a crucial cat-
alytic site of the enzyme reaction, and bred these mice
with those expressing cre-recombinase driven by the
albumin promoter to produce LKO mice. This approach
reduced hepatic SCD1 mRNA, protein, and SCD activity
to nearly undetectable levels without affecting SCD activ-
ity in other organs such as the adipose, muscle, and kid-
ney. Unlike GKO mice (Miyazaki et al., 2001b), LKO mice
did not have skin and eye phenotypes such as alopecia,
closed eye fissure, and atrophy of sebaceous glands.
We unexpectedly found that LKO mice were not pro-
tected from HF diet-induced obesity. The differential
metabolic response to HF diet between the current stud-
ies in LKO mice and ASO studies by Jiang et al. (Jiang
et al., 2005) is unlikely due to differences in diet or geno-
type: both studies used Research Diets RD12492 HF
diet and the C57BL/6 genetic background. The mice
used in the current studies had been backcrossed to
C57BL/6 for at least seven generations. We interpret this
collection of data to indicate that MUFA derived from en-
dogenous synthesis in extrahepatic tissues are compen-
sating for reduced hepatic MUFA production in LKO
mice. In fact, peritoneal injection of the ASO reduced
SCD1 expression in not only liver, but also adipose tissues
and possibly other tissues (Gutierrez-Juarez et al., 2006;
Jiang et al., 2005). Deletion of SCD1 in other tissues may
be necessary to cause a sufficient decrease in tissue
and circulating MUFA. MUFA derived from adipose tissue
influence the hepatic MUFA pool, and vice versa, due to
the hepatic and adipose secretion of MUFA in lipoproteins
or as free fatty acids, respectively. Therefore, the resis-
tance to HF diet-induced weight gain and hepatic steato-
sis requires SCD1 deficiency in an extrahepatic tissue, or
simultaneously in a combination of tissues, such as the
liver, adipose, and muscle.r Inc.
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HSVLF Diet Is Required for Lipogenic In-
duction in LKO Mice
(A) In vivo fatty acid synthesis was analyzed as
incorporation of 3H2O into fatty acids. Male
mice were fasted for 2 hr before the intraperito-
neal injection of 3H2O as described in Figure 3.
**p < 0.001 compared to lox counterparts. (B)
Srebf1 (SREBP-1c) and Mlxipl (ChREBP)
mRNA and (C) Nuclear SREBP-1, SREBP-2,
and ChREBP protein. Membrane and nuclear
fractions were isolated from fresh liver and
30 mg of the nuclear or membrane protein
was subjected to a Western blot analysis. (D)
mRNA involved in de novo lipogenesis. (E)
mRNA involved in glycolysis. Eight-week-old
animals were fed with chow diet, HSVLF diet,
or HSVLF diet supplemented with 20% (w/w)
of either tristearin (18:0) or triolein (18:1) for
10 days. Four-hour-fasted animals were sacri-
ficed with an isoflurane overdose. Total RNA
was purified with a TRI reagent and cDNA syn-
thesis was performed with a Superscript III
reverse transcriptase kit. Data are presented
relative to mRNA of L32 ribosomal protein in
the same samples. *p < 0.05 and **p < 0.001
compared to Lox counterparts (one-way
ANOVA using Student-Newman post-hoc
test). (F) TG secretion rate: male mice were
fasted for 4 hr before the intraperitoneal injec-
tion of P-407. Blood was collected by retro-
orbital puncture immediately before injection.
The TG secretion rate was calculated as the
difference in plasma TG over the 2 hr time inter-
val and is expressed as mmol/kg/h. Results are
expressed asmean ± SEM for n = 3–6mice per
group.LKO mice were also not protected from diet-induced
insulin resistance, whereas liver-specific SCD1 inhibition
achieved by intraportal ASO delivery increased hepatic
insulin sensitivity (Gutierrez-Juarez et al., 2006). The differ-
ence in insulin sensitivity phenotypes between this study
and the ASO study may be explained by acute versus
chronic inhibition and/or the inhibition potency. In addition,
hepatic insulin sensitivity in the studies ofGutierrez-Juarez
et al. was examined using the euglycemic insulin-clamp
technique, whereas only whole-body insulin sensitivity
wasevaluated inpresent study. Althoughproteins involved
in hepatic insulin signaling were not altered in LKO mice
under basal conditions (Figure 6B), the insulin-clamp eval-
uation is required for determining whether chronic liver-
specific inhibition of SCD1 alters hepatic insulin sensitivity.
Increased adiposity may be elicited not only by HF di-
ets, but also by overconsumption of carbohydrates, which
yields an abundance of the fatty acid precursor acetyl-
CoA. A high-glycemic load stimulates pancreatic insulinCell Mesecretion, which, together with dietary carbohydrate,
stimulates hepatic fatty acid synthesis by upregulating
lipogenic gene transcription via transcriptional and post-
transcriptional effects on the transcription factors
SREBP-1, ChREBP, and LXR (Horton et al., 2002; Iizuka
et al., 2004). Scd1 gene expression is highly responsive
to insulin and carbohydrates and its promoter contains
response elements for SREBP-1, LXR, and possibly
ChREBP (Chu et al., 2006; Iizuka et al., 2004; Tabor
et al., 1999). Our previous studies in GKOmice suggested
that SCD1 is critical for the upregulation of hepatic lipo-
genesis in response to feeding HC diets high in glucose
or fructose. In this study, we found that like GKO mice
(Figure S1), LKO mice are protected from carbohydrate-
induced adiposity and liver steatosis. In both long-term
(18 week HC diet) and short-term (2 week HSVLF diet)
studies, LKO mice had a decreased rate of hepatic fatty
acid synthesis and reduced induction of mRNAs encoding
enzymes of de novo lipogenesis (FAS, ACC, and Elovl6)tabolism 6, 484–496, December 2007 ª2007 Elsevier Inc. 491
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LKO Mice Fed a HSVLF Diet Is Rescued
by Oleate Supplementation
(A) Pyruvate tolerance test. Eight-week-old
male mice fed with either HSVLF or HSVLF
supplemented with oleate (18:1) for 10 days
were fasted for 4 hr. Two g/kg body weight of
pyruvate was administered by intraperitoneal
injection and blood was drawn at 0, 10, 30,
60, and 90 min after the injection.
(B) Phosphorylation state of IRS-1, AKT, ERK
and AMPK. Livers from Lox and LKO mice
were homogenized with a RIPA buffer in the
presence of protease and phosphatase inhibi-
tors. For the determination of p-IRS-1, the total
liver extract (400 mg) was immunoprecipitated
with anti-IRS-1 and the phosphorylation state
was detected with anti-phosphotyrosine.
Phospho- and total-AKT, ERK, and AMPK
levels were assayed by Western blot using
specific antibodies.
(C) mRNA involved in gluconeogenesis.
(D and E) PGC1 mRNA (D) and mRNA involved
in thermogenesis (E). Animals were fed with
chow diet, HSVLF diet, or HSVLF diet supple-
mented with 20% (w/w) of either tristearin
(18:0) or triolein (18:1) for 10 days. Four-hour
fasted animals were sacrificed with an isoflur-
ane overdose. Total RNA was purified with
a TRI reagent and cDNA synthesis was per-
formed with a Superscript III reverse transcrip-
tase kit. Data are presented relative to mRNA
of L32 ribosomal protein in the same samples.
*p < 0.05 and **p < 0.001 compared to Lox
counterparts (one-way ANOVA using Stu-
dent-Newman post-hoc test). Results are ex-
pressed as mean ± SEM.relative to Loxmice. Additionally, hepatic SCD1 deficiency
in LKO mice abrogated the increased hepatic TG secre-
tion rate observed in Lox mice fed the HSVLF or stea-
rate-supplemented diet, but the secretion rate was similar
between Lox and LKO mice fed the oleate-supplemented
diet. The observed differences in the TG secretion rate and
adiposity share a similar pattern, suggesting that delivery
of MUFA to adipose via VLDL and/or chylomicrons is
required for adiposity. Thus, unlike the HF diet, LKO
mice fed the HC diet reproduce many phenotypes of the
GKO mice. However, the phenotypes elicited by the
HSVLF diet in GKO mice (Flowers et al., 2006) are more
severe and pathological than those observed in LKO
mice, indicating that extrahepatic MUFA also influence
the HSVLF-induced phenotypes.
How does hepatic SCD1 regulate lipogenic gene tran-
scription? On a HSVLF diet, hepatic SCD1 deficiency
drastically reduced the nuclear levels of two major lipo-
genic transcription factors SREBP-1 and ChREBP. In ad-
dition, major hepatic carbohydrate metabolites such as
glycogen, glucose, G6P, F6P, F2,6BP, and X5P were de-
creased in the HSVLF LKO mice. Importantly, metabolite
levels and nuclear SREBP-1 and ChREBP content were
normalized by oleate, but not stearate, supplementation,
indicating that hepatic SCD1 expression and its product492 Cell Metabolism 6, 484–496, December 2007 ª2007 Elsevieoleate are required for normal glucose metabolism and
nuclear translocation of SREBP-1 and ChREBP proteins.
Several in vitro studies have shown that oleate has either
inhibitory or neutral effect on the SREBP-1 proteolytic
processing and gene expression (Hannah et al., 2001;
Worgall et al., 2002). Although the reason for the opposite
effect between in vitro and in vivo results is not clear, our
results strongly suggest that oleate alters lipogenesis
through a signaling pathway that is unique to in vivo
circumstance. We have recently observed that lipogenic
gene expression is normalized in GKO mice expressing
a constitutively active nuclear form of SREBP-1a in
the liver (unpublished data), suggesting that impaired
SREBP-1 processing is primarily responsible for the de-
creased lipogenesis due to hepatic SCD1 deficiency. We
currently do not understand the mechanism for the
reduced maturation of SREBP-1 due to SCD1 deficiency,
although it may involve increased expression of Insig2a in
the HSVLF LKOmice (Table S6). Additionally, a number of
studies have shown that glucose, fructose, or their metab-
olites independent of insulin stimulate hepatic SREBP-1c
expression and possibly maturation (Foretz et al., 1999;
Hasty et al., 2000). Another explanation is from a recent re-
port showing that glucose and G6P act as agonists of LXR
(Mitro et al., 2007), which also promotes the transcriptionr Inc.
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genes Fasn (FAS), Acaca (ACC), and Scd1 (Cha and Repa,
2007; Chu et al., 2006; Joseph et al., 2002; Repa et al.,
2000). Still another possibility is that hepatic oleate defi-
ciency alters membrane fluidity and integrity to affect
SREBP-1 maturation and translocation.
The translocation of ChREBP to the nucleus involves
a phosphorylation-dependent mechanism responsive to
hepatic levels of X5P (Kabashima et al., 2003). Hepatic
glucose flux through GLUT2 and glucokinase in hepato-
cytes promotes the formation of X5P via the hexose
monophosphate shunt, which activates protein phospha-
tase 2A to dephosphorylate ChREBP. The activated (de-
phosphorylated) ChREBP translocates into the nucleus
to promote the transcription of lipogenic genes such as
Fasn (FAS), Acaca (ACC), and Pklr (LPK). In LKO mice
fed HSVLF diet, the decreased levels of X5P and the asso-
ciated decrease in nuclear content of ChREBP likely con-
tribute to the reduction of lipogenesis in LKO mice. The
reduction of X5P in liver of LKO is partially due to lower
level of G6pdx (glucose-6-phosphate dehydrogenase),
which catalyzes a rate-limiting step of the hexose mono-
phosphate shunt (Table S6). In addition, the observed im-
pairment of gluconeogenesis in LKO mice (Figure 6A) and
consequent reduction in the hepatic concentration of G6P
(Figure 4E), which is original substrate for X5P production,
leads to a reduced level of X5P. These results indicate that
endogenous MUFA synthesis is not only important for
hepatic lipid metabolism, but also influences hepatic car-
bohydrate metabolism to affect hepatic levels of glucose,
G6P, and other intermediates.
Hypoglycemia, decreased hepatic glycogen, and lower
lipogenic gene expression were also observed in FAS
liver-specific knockout (FASLKO) mice fed a high-carbo-
hydrate fat-free diet (Chakravarthy et al., 2005), which is
comparable to the HSVLF diet used in the current LKO
studies. FAS deficiency leads to both saturated fatty
acid and MUFA deficiencies, whereas only MUFA defi-
ciency occurs in SCD1 deficiency. Since SCD1 is down-
stream of FAS and converts FAS-derived saturated fatty
acids to MUFA, it is possible that impaired hepatic MUFA
synthesis is responsible for many of the metabolic pheno-
types observed in both FASLKO and SCD1 LKO mice.
This model is supported by our finding that oleate, but
not stearate, supplementation of the HSVLF diet pre-
vented hypoglycemia phenotype in SCD1 LKO mice. Fur-
thermore, hypoglycemia in FASLKO mice was reversed
with administration of the PPARa agonistWY14,643, a po-
tent inducer of SCD1 (Miller and Ntambi, 1996), suggest-
ing that oleate production is required for maintaining nor-
mal glucose metabolism. We tested this hypothesis by
feeding a WY14,643-supplemented HSVLF diet to LKO
mice, which not only failed to rescue the hypoglycemia
and reduced adiposity phenotypes in LKO mice, but also
elicited these phenotypes in wild-type and Lox mice (Fig-
ure S4). The hypoglycemic effect of a WY14,643-supple-
mented fat-free diet has been previously reported to occur
in C57BL/6 wild-type mice, but not in mice on a mixed
strain background harboring theFASconditional knockoutCell Mallele (Chakravarthy et al., 2005). Furthermore, genetic
modifiers between the C57BL/6 and SV129 strains affect-
ing the physiological response to WY14,643 have been
suggested by others (Cunard et al., 2002). This strain de-
pendence precludes us fromaccurately testing the PPARa
hypothesis and beckons the question of whether oleate,
but not stearate, supplementation will rescue the meta-
bolic abnormalities of the FASLKOmouse. Another signif-
icant differencebetween theFASLKOandSCD1LKOmice
is the presence and absence of HC diet-induced hepatic
steatosis, respectively. This phenotypic difference is likely
due to accumulation ofmalonyl-CoA in theFASLKO,which
would inhibit the CPT-1-mediated mitochondrial import of
fatty acids for b-oxidation. In SCD1 LKO mice, intact FAS
activity and potentially reduced ACC activity would pre-
ventmalonyl-CoAaccumulation andpermit adequate fatty
acid oxidation to prevent hepatic steatosis.
What is the connection between oleate and energy sta-
tus and how does oleate deficiency lead to decreased he-
patic glucose and hypoglycemia? One possibility is that
hepatic SCD1 deficiency leads to enhanced hepatic insu-
lin signaling, resulting in suppression of gluconeogenesis
and enhanced glycolysis. However, we observed no ge-
notypic difference in the expression of the gluconeogenic
genes Pck1 (PEPCK) and G6pc (glucose-6-phosphatase)
between Lox and LKO mice on either the chow or HSVLF
diets (Table S6). Furthermore, we detected no difference
between Lox and LKO mice in the phosphorylation state
of several insulin signaling components such as IR, IRS-
1, IRS-2, and AKT (Figure 6 and data not shown). We pre-
viously reported that global SCD1 deficiency increases
the phosphorylation state of AMPK and its activity in liver
(Dobrzyn et al., 2004). However, phospho-AMPK levels
were not altered in the liver of LKO mice. These data
suggest that extrahepatic deletion of SCD1 is required
for the activation of AMPK in liver. In the FASLKO similar
to fasted PPARa-deficient mice (Kersten et al., 1999), it
is suspected that the hypoglycemia is secondary to an
impairment in hepatic gluconeogenesis due to a lack of
obligatory cofactors (ATP, NADH, and acetyl-CoA) result-
ing from decreased fatty acid oxidation (Xu et al., 2002).
LKO mice also have lower hepatic ATP levels (Table 1)
and an impaired rate of gluconeogenesis (Figure 6A)
despite normal gene expression for fatty acid oxidation.
In fact, we found that BHA levels tended to be higher in
LKOmice fed a HSVLF diet compared to Lox counterparts
(p = 0.08, Table S5). The lowered hepatic ATP is probably
due to increased uncoupling protein levels (UCP-2 and
UCP-5) in LKO mice. The supplementation of oleate, but
not stearate, normalized the expression of Ucp-2 and
Slc25a14 (UCP-5) and rescued impairment of gluconeo-
genesis. These results suggest that energy from carbohy-
drate is used for heat production instead of ATP synthesis
in the absence of oleate availability. We previously re-
ported a remarkable increase in UCP expression in liver
(Ucp-2), skeletal muscle (Ucp-2 and Ucp-3), and white
and brown adipose tissues (Ucp-1, Ucp-2, and Ucp-3) in
GKO mice (Lee et al., 2004; Miyazaki et al., 2004b).
Although the underlying mechanism of how SCD1 andetabolism 6, 484–496, December 2007 ª2007 Elsevier Inc. 493
Cell Metabolism
Hepatic SCD1 in Carbohydrate-Induced Obesityoleate deficiencies increase UCP expression remains to
be elucidated, the increased expression UCP was associ-
ated with induction of Ppargc1a (PGC-1a) expression.
Our results illustrate the existence of a tissue-specific
role of SCD1 that discriminates between carbohydrate-
and HF-induced obesity and hepatic steatosis. Further-
more, our data exemplifies a novel role for hepatic SCD1
expression in controlling carbohydrate and glucose
homeostasis. The pharmacological inhibition of SCD1 in
liver should have beneficial effects on carbohydrate-
induced adiposity, but the prevention of HF-induced obe-
sity requires inhibition of SCD1 in extrahepatic tissues
such as adipose tissue.
EXPERIMENTAL PROCEDURES
Generation of Scd1-Conditional Knockout Mice
DNA pools from a mouse strain 129/SV BAC library (Genome Systems
Inc.) were screened by PCR using a primer pair that amplified a portion
of the Scd1 gene. A BAC clone containing the mouse Scd1 gene was
identified and obtained from Genome Systems Inc. Portions of this
BAC were used to construct the Scd1 cKO targeting vector. We mod-
ified the pflox vector (generously provided by Jamie Marth, University
of California, San Diego) by removing the HSV-TK cassette originally
located adjacent to the Neo cassette by digestion with EcoRI. A
HSV-TK cassette was placed at the junction between the 30 homology
unit and the cloning vector. Three contiguous regions of the Scd1 gene
were introduced into this vector: a 3.7 kb EcoR I-Nsi I 50 homology unit
located upstream of exon 3, a 0.7 kb Nsi I-EcoR I fragment containing
exon 3 placed between 2 loxP sites, the floxed Neo cassette, and a
2.6 kb EcoR I-SmaI 30 homology unit located 30 to exon 3. A Pac I re-
striction site located at the junction between the cloning vector and the
50 homology unit was used to linearize the final targeting vector. The
Scd1-cKO targeting vector was linearized by digestion with Pac I
and introduced by electroporation into murine SV/129 R1 embryonic
stem cells. ES cells that integrate the targeting vector either by homol-
ogous or random integration were selected by growth on G418. The
presence of gancyclovir (GANC) selects against clones that retained
the HSV-TK cassette, thus enriching for clones that integrated the
Neo cassette by homologous recombination. 432 Neor, GANCr colo-
nies were selected, replicated, and expanded. DNA was isolated
from replica ES clones, digested with Pvu II, electrophoresed on aga-
rose gels, transferred to charged nylon membranes and hybridized to
radiolabeled 30 probe. Eighty correctly targeted clones were identified
by the appearance of an additional 6.9 kb Pvu II band in addition to the
13.6 kb native Pvu II band. DNA from replicas of 37 of the clones that
appear to be correctly targeted on the 30 sidewere digestedwith Pvu II,
electrophoresed on agarose gels, transferred to charged nylon mem-
branes and hybridized to radiolabeled 50 probe. Twenty-nine correctly
targeted clones were identified by the appearance of an 8.7 kb band in
addition to the 13.6 kb native band when hybridized to the 30 probe.
DNA sequence analysis of 12 of these clones confirmed the presence
of the floxed exon 3 and the floxed Neo cassette. Three karyotypically
normal targeted clones were injected into C57BL/6 blastocysts at the
Transgenic Animal Facility of the University of Wisconsin. Chimeric
founders that transmitted the planned modification of the Scd1 gene
to their progeny were obtained from the 4F9 targeted ES cell line. Chi-
meric male mice were bred with C57BL/6 and germ-line transmission
confirmed by PCR and Southern blot analysis.
The resulting Scd1lox/+ mice were backcrossed either 6 times or
10 times with C57BL/6 mice. Scd1lox/+ mice were intercrossed with
C57BL/6J Albumin Cre mice obtained from the Jackson Laboratory
to generate compound heterozygous (Scd1lox/+;Cre/+) mice. Double
heterozygous mice were crossed with Scd1lox/lox mice to obtain
Scd1lox/lox;Cre/+ (LKO) mice. Mice were maintained on a 12 hr light/
dark cycle with free access to water and either a standard chow diet494 Cell Metabolism 6, 484–496, December 2007 ª2007 Elsev(Purina 5008) or special diets (HF diet RD12492 and HC diet RD
12450B from Research Diets Inc., HSVLF diet TD03045 from Harlan
Teklad Inc.) and housed in specific pathogen-free barrier facility. The
caloric contributions (% fat: % carbohydrate: % protein; kcal/g) for
the chow, HC, HF, and HSVLF diets as indicated by the manufacturer
are (chow, 16.7: 56.4: 26.8; 3.50 kcal/g), (HC, 10: 70: 20; 3.85 kcal/g),
(HF, 59.9: 20.1: 20.0; 5.24 kcal/g), and (HSVLF, 2.6: 76.7: 20.7;
3.53 kcal/g). Animals were fasted for 4 hr and sacrificed by an over-
dose of isoflurane anesthesia, and tissue from liver, adipose, and skel-
etal muscle were rapidly removed, snap-frozen in liquid nitrogen, and
stored at 80C until processed for experiments. All in vivo experi-
mental procedures were approved by the animal care research com-
mittee of the University of Wisconsin-Madison. Genotyping was
performed by PCR using genomic DNA isolated from a tail tip as pre-
viously described. The primer sequences for the cre transgenes were
available at the Jackson Laboratory. For Scd1lox genotyping, we used
primers as follows: primer A, 50 CCC TAA CTG CTT CAT GTT C 30;
primer B, 50 CTT ATG ACA AGT GCC CAG 30; primer neo, 50 ATA
GCA GGC ATG CTG GGG AT 30.
Analytical Procedures
Glucose tolerance tests were performed on mice fasted for 4 hr, while
insulin tolerance tests were performed in the fed state. Animals were
administrated with either 2 g/kg body weight of glucose or 0.75 U/kg
body weight of human insulin (Novo Nordisk) by oral gavage or intra-
peritoneal injection, respectively. Pyruvate tolerance test was also
performed on mice fasted for 4 hr. Two g/kg body weight of sodium
pyruvate (Sigma) dissolved in saline was intraperitoneally injected
and blood was drawn at the indicated time after the injection. Plasma
glucose was measured using a glucose oxidase method. Plasma insu-
lin was measured using the insulin RIA kit (Linco Research). Plasma
cholesterol and TG were analyzed by colorimetric enzyme assay using
the Infinity TG and cholesterol reagents (Thermo Electron). BHA levels
were measured using a colorimetric assay kit (Stanbio Laboratories).
Tissue TG, ceramide, DAG, free fatty acid, phospholipid, and choles-
teryl ester contents were analyzed by gas-liquid chromatography as
described previously (Dobrzyn et al., 2005a, 2005b; Miyazaki et al.,
2001a). Plasma samples for lipoprotein analysis were prepared as
described previously. Lipoproteins were fractionated on a Superose
6 10/300 GL FPLC column (Amersham Biosciences). Fractions
(500 ml) were collected and used for triglyceride and cholesterol anal-
ysis (Miyazaki et al., 2000).
Determination of Carbohydrate Metabolite Concentrations
Frozen livers were weighed and homogenized in 0.5 M ice-cold
perchloric acid using a Polytron homogenizer kept on ice during the
homogenization. The homogenates were centrifuged and superna-
tants neutralized for use in the assays. The following glycolytic and
nonglycolytic metabolites were determined by means of enzyme-
coupled spectrometric assays as indicated previously (Dentin et al.,
2004; Hagopian et al., 2003;Miyazaki et al., 2004a): glucose, glycogen,
lactate, pyruvate, G6P, F6P, fructose-1,6-biphosphate (F1,6BP), glyc-
eraldehydes-3-phosphate (GAP), and X5P. F2,6BP was the only
metabolite that was extracted in an alkali medium (0.05 M NaOH),
and the pH of the extract maintained at > pH 11.0.
SCD Assay
Microsome fractions were isolated by sequential centrifugation as pre-
viously described (Miyazaki et al., 2006). SCD assay was performed at
room temperature in the presence of 100 mM 14C-stearoyl-CoA, 2 mM
NADH, and 50 mg microsomal protein. The SCD activity was analyzed
as a production of oleate from stearoyl-CoA.
In Vivo Lipogenesis Rate
Animals were fasted for 2 hr and were injected intraperitoneally with
50 mCi of 3H2O in 0.2 ml of saline. After 1 hr, animals were sacrificed
by isoflurane overdose, and approximately 500 ml of blood was col-
lected by cardiac puncture to determine the 3H-specifc activity. Theier Inc.
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KOH in 70%Ethanol at 85C for 1 hr. The saponified liver was acidified,
and the lipids were extracted with hexane. Free sterols and fatty acids
were separated on TLC with heptane/isopropyl ether/acetic acid
(60/40/3) as the mobile phase. The rate of cholesterol and fatty acid
synthesis were calculated as mmols of 3H-radioactivity incorporation
into sterol and fatty acid fractions, respectively, per hour per gram of
liver (Shimano et al., 1996).
Real-Time Quantitative PCR
Total RNA was extracted with TRI reagents (Molecular Research).
DNAase-treated total RNA (0.9 mg) was reverse-transcribed with either
Superscript III (Invitrogen) or iSCRIPT (BioRad). Real-time quantitative
PCRwas performed on an ABI Prism 7500 Fast instrument using gene-
specific primers. The primer sequences are available upon a request.
SYBR green was used for detection and quantification of given genes
expressed as mRNA level normalized to a ribosomal housekeeping
gene (Arbp or L32) using the DDCt method.
Western Blot
For the immunoblotting of the SREBP and ChREBP proteins, nuclear
extracts andmembrane fractions of mice livers were prepared accord-
ing to the methods of Shimomura et al. (1997). Aliquots of nuclear and
membrane fractions (30 mg each) were mixed with SDS loading buffer,
subjected to SDS/PAGE on an 8% gel, and transferred to Immobilon-P
membranes. After blocking with 3% BSA in TBS buffer (pH 8.0) plus
Tween 20 at 4C overnight, the membranes were washed and incu-
bated with polyclonal anti-SREBP-1, SREBP-2 (kindly provided by
Dr. Jay Horton) or ChREBP (Cayman Chemicals) as primary antibody
and anti-rabbit IgG-HRP conjugate as the secondary antibody. Visual-
ization of the proteins was performed with Western blotting detection
system kit from Pierce Biotechnology (Rockford, IL). For immunopre-
cipitation of insulin receptor, liver samples were homogenized in
a buffer that contained 50 mMHEPES (pH 7.4), 2 mM sodium orthova-
nadate, 10 mM sodium fluoride, 2 mM EDTA, 1% NP-40, 0.25%
sodium deoxycholate, and protease inhibitors (Sigma). Homogenates
(400 mg) were then immunoprecipitated with 1.2 mg of primary antibody
to IRS-1 (Santa Cruz Biotechnology). Samples were subjected to 8%
SDS-PAGE and transferred to Immobilon-P transfer membrane. The
membranes were immunoblotted with anti-phosphotyrosine anti-
bodies (Upstate Biotechnology). Antibodies for phosphorylated and
total Akt, ERK, and AMPK were purchased from Cell Signaling, Santa
Cruz Biotechnology, and Upstate Biotechology, respectively. The
antibody for SCD1 was purchased from Santa Cruz Biotechnology
(SC-14719) and is raised against an N-terminal epitope of mouse
SCD1.
TG Secretion Rate
Hepatic TG secretion rates were determined by measuring the tempo-
ral increase in plasma TG after inhibition of lipoprotein lipase by intra-
peritoneal injection of poloxamer 407 (P-407; BASF Corp.) as decribed
previously (Millar et al., 2005). Briefly, mice were fasted for 4 hr and
then administered P-407 at 1 g/kg. Blood was collected by retro-
orbital puncture immediately before injection and at 30, 60, and
120min after injection. The TG secretion rate was calculated as the dif-
ference in plasma TG over the 2 hr time interval and is expressed
as mmol/kg/hr.
Body Temperature and Cold Exposure
Body temperatures were measured with a digital thermometer (model
4600; Yellow Springs Instruments, Yellow Springs, OH). Core temper-
atures were measured rectally in mice fed a chow diet or HSVLF diet
for 10 days. For cold tolerance test, animals fed the HSVLF diet were
placed in a 4C cold room for 24 hr and their rectal temperatures
were measured at 0, 1, 2, 3, 6, 12, and 24 hr.Cell MeSupplemental Data
The Supplemental Data include four supplemental figure and six
supplemental tables and can be found with this article online at
http://www.cellmetabolism.org/cgi/content/full/6/6/484/DC1/.
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